European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S.

Hikma Pharmaceuticals (OTCPK:HKMPF) announced on Thursday that it has acquired the FDA-approved Abbreviated New Drug ...

TG Therapeutics' Briumvi has shown strong revenue growth, with $310 million in FY24, and is expected to reach $540 million in ...

Besides, Novartis, Johnson & Johnson plans to spend $55 billion over four years on domestic manufacturing, research and technology. Merck announced plans to spend $1 billion on a vaccine ...

Novartis NVS shares ended the last trading session 4% higher at $107.52. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...

Shares in Swiss drugmaker Novartis (NVS) were looking perkier today as it set out plans to invest $23 billion in U.S. manufacturing to beat the tariffs threat against the industry. Discover ...

Novartis saying on Thursday plans to spend $23 billion to build and expand 10 facilities in the US as it grapples with renewed threats of drug import duties from the Trump administration ...

Featured Earnings W. R. Berkley Corporation (NYSE:WRB) (Q1) EPS of $1.01, compared to $1.04 in the prior-year quarter.